Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimer
December 6, 2018 8:56 AM ESTOppenheimer analyst Jay Olson lowered the price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to $10.00 (from $14.00) while maintaining a Outperform rating.
Olson commented, "CNAT top-lined results from the Ph2b ENCORE-PH trial in 240 patients with compensated or early decompensated (~24% of patients) NASH cirrhosis... More
Conatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary Endpoint
December 6, 2018 6:20 AM ESTConatus Pharmaceuticals Inc. (Nasdaq: CNAT) today announced top-line results from the companys Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trials primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from baseline to Week 24 in any of three emricasan dosing groups compared with placebo. In the overall trial population, changes in HVPG from baseline to Week 24 showed trends consistently favoring emricasan compared with placebo but did not meet the primary endpoint.
The total patient population was... More
Stifel Downgrades Conatus Pharmaceuticals (CNAT) to Hold
December 6, 2018 3:54 AM ESTStifel analyst Stephen Willey downgraded Conatus Pharmaceuticals (NASDAQ: CNAT) from Buy to Hold with a price target of $4.00 (from $10.00).
For an analyst ratings summary and ratings history on Conatus Pharmaceuticals click here. For more ratings news on Conatus Pharmaceuticals click here.
Shares of Conatus Pharmaceuticals closed at $4.50 yesterday.
... More